- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05805358
Hyperpolarized 13C MRI for Cancer Immunotherapy (DNPSPIO)
Next Generation Precision Imaging for Cancer Immunotherapy: Dynamic Nuclear Polarization and Metabolomics Study
Study Overview
Status
Intervention / Treatment
Detailed Description
The investigators plan a 3-year trial with a randomized, two-groups allocation observational study design that will enroll 90 subjects with newly diagnosed or recurrent gynecological cancer from Linkou Chang Gung Memorial Hospital (CGMH) receiving ICI therapy for this prospective study. Standard cares, eg. MRI/CT/PET, are priorly required for the first-line screening method, with tumor slides and routine blood work at the initial visit. After being randomly assigned, 30 eligible subjects will be assigned to the next-generation imaging group, and will receive two integrated examinations between the baseline and 2 weeks of immunotherapy-the integrated examination of DNP and metabolomics.
Subjects in the next-generation imaging group will receive splenic DNP imaging, followed by non-contrast-enhancing MRF at the lesion and MR Relaxometry, which provide quantitative measurements of metabolism occurring within the spleen and within the cancer cells, respectively. DNP is injected with 13C contrast agent hyperpolarized 13C pyruvate (HP [1-13C] Pyruvate) intravenously in the arm, and the study drug is injected at a dose of 0.43 ml/kg, which is labeled with the non-radioactive isotope 13C at the C1 position, hyperpolarized 13C signals are obtained through MR spectrum acquisition, and then MRF sequences are performed to obtain multi-parameter tissue characteristics. The general imaging group will receive the same MR strategies but without spleen DNP scan.
All MRI sequences will be performed on a 3T clinical scanner (Discovery MR750w,GE Healthcare, Milwaukee, USA) with a flexible surface 13C/1H multinuclear transmit-receive coil (RAPID Biomedical, Bavaria, Germany) to cover the splenic region.
DNP-MRI:
To comply with the Good Manufacturing Practice (GMP) of pharmaceuticals, [1-13C]pyruvate for human will be prepared in the ISO 8 clean room and ISO 5 laminar flow in the Department of Nuclear Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan. The premixed [1-13C]pyruvic acid/12.5 mM Electronic Paramagnetic Agent (Electronic Paramagnetic Agent; EPA; AH111501, GE Healthcare, Oslo, Norway) will be packed into a sterile pharmacy Kit (Sterile Fluid Path; SFP, GE Research Circle Technology) and polarized in the polarizer (SPINlab, GE Research Circle Technology) at 0.7 - 0.8 K and a magnetic field of 5 T for at least 2 - 3 hrs. After being quickly dissolved in heated water, it will pass through an EPA filter to remove excess EPA and be mixed with neutralization medium (NaOH/TRIS/EDTA) in the receiver, and then automatically detected by optical measurement in the QC machine (GE GE Research Circle Technology), including pyruvate concentration, EPA concentration, pH, temperature, volume, and polarization level, while simultaneously drawing a solution containing hyperpolarized [1-13C]pyruvate through a 0.2 μm terminal filter (ZenPure, Manassas, Virginia) into an administration syringe (Medrad, Warrendale, Pennsylvania) to ensure sterility. After the responsible physician checks that the QC parameters meet the criteria, the patient will be injected intravenously at a dose of 0.43 mL/Kg at a flow rate of 5 mL/s, and then flushed with 20 mL of physiological saline. Terminal filter integrity (Threshold = 50 psi) will be checked immediately after dispensing.
During 13C-MRI scanning, a set of image detections will be performed first for positioning, and then the 13C signal will be calibrated, including gradient shimming, 13C center frequency confirmation (calculated from the 1H center frequency) and emission gain optimization (using the Bloch-Sieger sequence ), after a 30-second delay from injection, the following rapid 13C sequence will be performed, which will take approximately 2-3 minutes:
- Pulse acquisition of 13C spectra: flip angle = 10°; TR = 2000 ms; slice thickness = 30 mm; read bandwidth = 5000 Hz; spectral collection points 2048; repetition = 14; acquisition time = 2000 ms; time-resolved Rate = 2000 ms.
- 13C metabolite-specific imaging of pyruvate, lactate, and alanine (spectral-spatial RF pulses followed by helical readout): TR = 250 ms; TE = N/A; in-plane spatial resolution = 10 x 10 mm^2; matrix size = 128 x 128 mm^2; field of view = 22 x 22 cm^2; slice thickness = 20 mm; flip angle = 15°/30°/30° (pyruvate/lactate/alanine); acquisition time = 250 ms; time resolution = 1000 ms.
- 13C chemical shift imaging: TR = 80ms; TE = N/A; in-plane spatial resolution = 25 x 25 mm^2; matrix size = 8 x 8 mm^2; field of view = 20 x 20 cm^2; slice thickness = 20 mm ; Flip angle = 15°; Acquisition time = 80 ms.
DWI:
The clinical MR study will continue after 13C DNP with the original scanner and will use single-echo planar technique with fat suppression (repetition time ms/echo time ms: 3300/79; number of signal averages: 4; slice thickness: 4 mm ; gap; 1 mm; matrix: 128x128 mm^2; field of view 20 x 20 cm^2). The highest b-value of 1000 sec/mm^2 has been chosen to optimize the signal-to-noise ratio. Diffusion-weighted gradients are applied orthogonally for slice selection, phase encoding and readout direction, and the slope will be calculated from the logarithmic decay curve of signal intensity versus b-value (Syngo, Siemens, Erlangen, Germany).
MR Fingerprinting (MRF):
MAGiC (MAGnetic resonance image Compilation) will use 2D fast spin echo based multi-saturation delayed multi-echo acquisition. Steady-state free precession (SSFP) is used for MRF acquisition with acquisition traces interleaved using 89 under sampled golden angle helices, sampling bandwidth = ±250 kHz, TR = 9 ms, TE = 2.2 ms, NEX = 1 and 979 frames . B0 and B1 are not included in the sequence but slice outlines are included to improve T2 accuracy, other imaging parameters used in MAGiC and MRF scans are: FOV = 22 x 22 mm^2; matrix = 256 x 256; slice thickness = 4 mm, 1 mm gap; 20 pieces. Time intervals of scan are approximately 4 minutes and 3.6 minutes, respectively.
MR Relaxometry:
The iterative decomposition of water and fat with an echo asymmetry at least-square estimation-iron quantification (IDEAL-IQ) sequence has the following parameters: TR 10 ms; TE 4.7 ms; echo number 6, ranging from 1.1 ms to 6.38 ms FOV 35-40 cm; matrix size 128 × 128; pixel bandwidth 325 Hz; flip angle 6; slice thickness 10 mm; space between slices 5 mm. The scans are acquired during a breath-hold lasting less than 30 seconds. R2* is calculated using the following formula: R2*IDEAL = -1.276 + 1.2366 * R2*GRE. R2* is then converted to iron concentration (mg/g) using the widely used formula proposed by Wood et al.: Iron concentration = 0.202 + 0.0254 x R2*
While there is no accepted normal range for spleen iron, 1.98 mg/g is suggested as an upper limit, with 2.74 mg/g reported to be pathological. Splenic iron varies by age and sex. Spleen iron content is higher in men than in women (men: 0.96 ± 0.34 mg/g, women: 0.87 ± 0.29 mg/g). In women, menopause is associated with 0.12 mg/g higher spleen iron. It must be noted that the GRE echo time of abdominal MRI is insufficient to quantify iron when iron exceeds the threshold (approximately 4 mg/g)
Metabolomics:
Plasma, urine and/or tissue samples collected from patients will be further analyzed by 1H high-resolution NMR (Bruker 600MHz NMR spectrometer) and LC-TOFMS (Waters Q-TOFMS) located at the Clinical Metabolomics Center, Chang Gung Memorial Hospital. Standard metabolomics software - GeneSpring MS, Markerlyn XS and Metaboanalyst, will also be used for multivariate data analysis and presentation. The METLIN, HMDB, and KEGG databases will be searched for an accurate set of features showing significant differences between the groups of before and after immunotherapies. Compound predictions will be performed using metabolite databases and formula generation software. Non-commercial and commercial applications such as MetaboAnalyst for metabolomics studies are also available. Laboratory examinations include routine inflammatory indices, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin, plasma antioxidant index (TAC), cellular antioxidant index (GPX), DNA damage index (8-OHdG ) and lipid oxidation and inflammation index (MPO); conventional metabolic indexes, such as LDH, lactate and pyruvate; and immune function-related indexes, such as T Cell & B Cell, T Cell Subset tests, HLA-B27, IL-6, a1-globulin and a2-globulin. If the patient has undergone slides for histopathological diagnosis, tissue LDH and MCT protein expression will also be determined.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Gigin Lin, MD, PhD
- Phone Number: 2575 886-3-3281200
- Email: giginlin@cgmh.org.tw
Study Contact Backup
- Name: Kuan-Ying Lu, MS
- Phone Number: 2602 886-3-3281200
- Email: fantacy52317@gmail.com
Study Locations
-
-
Guishan District
-
Taoyuan City, Guishan District, Taiwan, 333
- Chang Gung Memorial Hospital
-
Contact:
- Gigin Lin, MD, PhD
- Phone Number: 2575 886-3-3281200
- Email: giginlin@cgmh.org.tw
-
Contact:
- Kuan-Ying Lu, MS
- Phone Number: 2602 886-3-3281200
- Email: fantacy52317@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newly diagnosed or recurrent gynecological cancer confirmed by histology.
- Age ≥ 20 years old.
- Expected to receive immunotherapy.
Exclusion Criteria:
- Suffering from other malignancies (excluding non-melanoma skin cancer).
- History of splenic abnormalities (such as splenic damage, cirrhosis-related splenomegaly or primary/metastatic splenic tumors).
- Insufficient function of bone marrow, liver and kidney.
- Contraindications to MRI studies (e.g. claustrophobia, cardiac pacemaker, metal implants in the pelvis).
- Uncontrolled concurrent diseases, including but not limited to kidney stones, persistent or active infection, symptomatic heart failure, unstable angina, cardiac arrhythmias, or mental illness/social situations that limit compliance with research requirements.
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Conventional Imaging Group
60 participants who accepted ICI treatment will receive conventional imaging
|
|
Experimental: Next Generation Imaging Group
30 participants who accepted ICI treatment will receive next generation imaging including MRF and MR Relaxometry and hyperpolarized 13C pyruvate DNP scanning.
|
DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DNP conversion flux ( pyruvate-to-lactate conversion rate; Kpl) before immunotherapy
Time Frame: ~1-2 weeks before clinical immunotherapies
|
To predict the response of immunotherapy
|
~1-2 weeks before clinical immunotherapies
|
DNP conversion flux ( pyruvate-to-lactate conversion rate; Kpl) after immunotherapy
Time Frame: Within 2 weeks after clinical immunotherapy
|
To predict the response of immunotherapy
|
Within 2 weeks after clinical immunotherapy
|
DNP conversion flux (area under the curve; AUC) before immunotherapy
Time Frame: ~1-2 weeks before clinical immunotherapy
|
To predict the response of immunotherapy
|
~1-2 weeks before clinical immunotherapy
|
DNP conversion flux (area under the curve; AUC) after immunotherapy
Time Frame: Within 2 weeks after clinical immunotherapy
|
To predict the response of immunotherapy
|
Within 2 weeks after clinical immunotherapy
|
Clinical 18FDG PET standardized uptake values (SUV) before immunotherapy
Time Frame: ~1 month before clinical immunotherapy
|
To predict the response of immunotherapy
|
~1 month before clinical immunotherapy
|
Clinical 18FDG PET standardized uptake values (SUV) after immunotherapy
Time Frame: ~2 months after clinical immunotherapy
|
To predict the response of immunotherapy
|
~2 months after clinical immunotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI/CT size measurement of the primary tumor at the end of immunotherapy
Time Frame: Up to 6 months
|
To predict the response of immunotherapy
|
Up to 6 months
|
Recurrent rate
Time Frame: History tracking for half to five years
|
Correlate the prognosis with the primary and the secondary outcomes
|
History tracking for half to five years
|
Survival rate
Time Frame: History tracking for half to five years
|
Correlate the prognosis with the primary and the secondary outcomes
|
History tracking for half to five years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gigin Lin, MD, PhD, Chang Gung Memorial Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Endometrial Neoplasms
Other Study ID Numbers
- 202201907A0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Hyperpolarized 13C-Pyruvate injection
-
University of Texas Southwestern Medical CenterEnrolling by invitationTraumatic Brain InjuryUnited States
-
University of Texas Southwestern Medical CenterEnrolling by invitationBreast NeoplasmsUnited States
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruiting
-
Sunnybrook Health Sciences CentreWithdrawn
-
Robert Bok, MD, PhDNational Cancer Institute (NCI); National Institute for Biomedical Imaging... and other collaboratorsRecruitingAdvanced Solid TumorUnited States
-
University of California, San FranciscoGE HealthcareCompleted
-
University of Texas Southwestern Medical CenterRecruitingDuchenne Muscular Dystrophy | Becker Muscular Dystrophy | Dilated Cardiomyopathy | Cardiomyopathy, Hypertrophic | Heart Failure With Reduced Ejection Fraction | Cardiac Sarcoidosis | Heart Failure With Preserved Ejection FractionUnited States
-
University of Texas Southwestern Medical CenterRecruitingBrain Tumor AdultUnited States
-
Rahul AggarwalNational Cancer Institute (NCI)TerminatedProstate CancerUnited States
-
Zhen Wang, MDAmerican Cancer Society, Inc.RecruitingRenal Cell Cancer | Kidney Neoplasm | Benign Kidney NeoplasmUnited States